The FDA has granted fast track designation to several oncology drugs, although the exact timing of these designations is unclear, with some reports indicating it occurred in February 2026 and others suggesting it happened in April 2026. The designations appear to cover a range of cancer types, including breast cancer, metastatic urothelial cancer, high-grade glioma, and lung cancer. The specific drugs and therapies involved include AKY-1189, FG001, and an inhalable gene therapy for lung cancer, among others.